ÖÜ¿¯ 1997Äê1Ô´´¿¯£¨×ܵÚ319ÆÚ£© µÚ12¾í µÚ11ÆÚ 2008Äê3ÔÂ11ÈÕ³ö°æ


Ð£ËÀ´óÊóѪ¹ÜÉú³É¹ý³ÌÖÐѪ¹ÜÉú³ÉËØ1¼°ÆäTie2ÊÜÌåµÄ±í´ï**¡îÿ

ËïÀö½Ü£¬´Þ Ãù£¬Íõ×ôÑÒ£¬·ëк㣬ë½ÚÃ÷£¬³Â·ïÈÙ


¿ÎÌâ±³¾°£ºÖÎÁÆÐÔѪ¹ÜÐÂÉúÊǽüÄêÀ´È±ÑªÐÔ¼²²¡ÖÎÁƵÄÑо¿°Ðµã£¬ÒÑÓжàÖÖ²»Í¬µÄѪ¹ÜÉú³ÉÒò×ÓÓ¦ÓÃÓÚ¼±ÐÔÐ£ËÀµÄʵÑéÐÔÖÎÁÆ¡£È»¶øÑª¹ÜÉú³ÉÊÇÒ»¸ö¶àÒò×Ó¹²Í¬²ÎÓëµÄ¸´ÔÓ¹ý³Ì£¬Ã¤Ä¿Ó¦ÓÃÕâЩѪ¹ÜÉú³ÉÒò×Ó¶ø½øÐеÄѪ¹ÜÉú³ÉÖÎÁƱؽ«Ôì³ÉÑÏÖØ²»Á¼ºó¹û¡£±¾ÊµÑé»ùÓÚ´Ë£¬½¨Á¢Ð£ËÀÄ£ÐÍ£¬Ä¿µÄÔÚÓÚÁ˽âÐ£ËÀµÄ×ÔÈ»²¡Àí¹ý³ÌÖÐAng1µÄ±í´ïÇé¿ö£¬´Ó¶øÎªAng1µÄѪ¹ÜÉú³ÉÖÎÁÆÌṩһ¶¨µÄÀíÂÛÒÀ¾Ý¡£

Æ«Òлò²»×㣺ÓÉÓÚʱ¼ä¼°ÊµÑéÌõ¼þËùÏÞ£¬±¾ÊµÑé½ö´Ó»ùÒòˮƽ¶ÔAng1ºÍTie2µÄ±í´ïˮƽ½øÐгõ²½ÌÖÂÛ£¬È±·¦¶ÔѪ¹ÜÉú³É¹ý³ÌÖÐAng1/Tie2µÄµ°°×±í´ïˮƽ¼°ÆäÊÜÌåºóˮƽµÄ·ÖÎö£¬ÒÔ¼°Ñª¹ÜÉú³É¹ý³ÌµÄÆäËûÖØÒªÒò×ӵıí´ï¼°ÆäÏ໥֮¼äµÄ¸´ÔÓ¹ØÏµµÄ̽ÌÖ£¬ÉÐÐèÒª½øÒ»²½µÄʵÑéÀ´½øÐÐÍêÉÆ¡£

ͬÐÐÆÀ¼Û£ºÊµÑéͨ¹ý½áÔú´óÊó¹ÚÂöǰ½µÖ§ÖÆÔìÐ£ËÀÄ£ÐÍÀ´Ñо¿Ð£ËÀºó¹£ËÀ²¿Î»¼°ÆäÖÜΧ×éÖ¯Ang1/Tie2µÄ±í´ï¼°ÆäÓëѪ¹ÜÉú³ÉµÄ¹ØÏµ£¬ÎªÁÙ´²ÕïÖÎÏà¹Ø¼²²¡ÌṩÁËÒ»¶¨Ë¼Â·£¬¾ßÓÐÒ»¶¨´´Ð¡£

±±¾©´óѧµÚÈýÒ½ÔºÐÄÄÚ¿Æ£¬±±¾©ÊÐ 100083

ËïÀö½Ü¡î£¬Å®£¬1978ÄêÉú£¬±±¾©ÊÐÈË£¬2006Äê±±¾©´óѧҽѧ²¿±ÏÒµ£¬²©Ê¿£¬Ö÷Òª´ÓʹÚÐIJ¡·¢²¡»úÖÆ¼°ÆäÖÎÁƵÄÑо¿¡£
lijiesun@126.com

ͨѶ×÷Õߣº´Þ Ãù£¬¸±Ö÷ÈÎҽʦ£¬±±¾©´óѧµÚÈýÒ½ÔºÐÄÄÚ¿Æ£¬±±¾©ÊÐ 100083

¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ð×ÊÖúÏîÄ¿
(30371562)*£»½ÌÓý²¿²©Ê¿µã»ù½ðÏîÄ¿
(20010001096)*

ÕªÒª
Ä¿µÄ:ͨ¹ý¼ì²âÕý³£Ðļ¡×éÖ¯¼°Ð£ËÀºóѪ¹ÜÉú³ÉËØ1¼°ÆäÊÜÌåTie2ÊÜÌå mRNAµÄ±í´ïˮƽ£¬Ì½ÌÖÆäÔÚÐ£ËÀºóµÄѪ¹ÜÐÂÉú¹ý³ÌµÄ×÷Óá£
·½·¨£ºÊµÑéÓÚ2006-04/2007-04ÔÚ±±¾©´óѧҽѧ²¿ÉúÎﻯѧÓë·Ö×ÓÉúÎïѧ»ùÒò×éʵÑéÊÒÍê³É¡£½«40Ö»ÐÛÐÔSD´óÊóËæ»ú·ÖΪ¼±ÐÔÐ£ËÀ×éºÍ¼ÙÊÖÊõ×飬¼±ÐÔÐ£ËÀ×éͨ¹ý½áÔúǰ½µÖ§½¨Á¢Ð£ËÀÄ£ÐÍ£¬¼ÙÊÖÊõ×éÖ»´©Ïß²»½áÔú¡£ÓÚÊõºó3£¬7£¬14£¬28 d Ëĸöʱ¼äµã£¬Ã¿×éÈ¡5Ö»´¦ËÀ£¬È¡ÐÄÔà×óÊÒǰ±Úͬһ²¿Î»£¬ÌáÈ¡×ÜRNA£¬ÓÃRT-PCRµÄ·½·¨£¬ÒÔGAPDH»ùÒòΪÄڲΣ¬½øÐа붨Á¿·ÖÎö¼ì²âÕý³£ÐÄÔ༰¹£ËÀºóѪ¹ÜÉú³ÉËØ1¼°Tie2 mRNAµÄ±í´ï£»Í¬Ê±ÓÃÃâÒß×黯µÄ·½·¨¼ì²â¸÷ʱ¼äµã¹£ËÀÇøÓòÒÔ¼°¹£ËÀÖܱßÇøÓòѪ¹ÜÊýÁ¿¡£ÊµÑé¹ý³ÌÖж¯Îï´¦Ö÷ûºÏ¶¯ÎïÂ×Àíѧ±ê×¼¡£
½á¹û£º40Ö»´óÊó½øÈë½á¹û·ÖÎö¡£Ñª¹ÜÉú³ÉËØ1¼°Tie2ÔÚÕý³£Ðļ¡×éÖ¯ÖоùÓÐËù±í´ï¡£ÔÚÐ£ËÀºóµÄ28 dÄÚ£¬Ñª¹ÜÉú³ÉËØ1ά³ÖÔÚÏà¶Ô²»±äµÄˮƽ£¬¶øTie2µÄ±í´ïÔÚÐ£ËÀºó3 dÂÔÓÐÉý¸ß£¬ÓÚ7 dºó´ï¶¥·å£¬14 dºó»Ö¸´Õý³££»¼±ÐÔÐ£ËÀºó7 d, ¹£ËÀÇø¼°¹£ËÀÖܱßÇøÓòµÄѪ¹ÜÊýÁ¿¾ùÃ÷ÏÔÔö¶à£¬²¢²»ËæÊ±¼äµÄÑÓ³¤¶ø¸Ä±ä£¬Î¬³ÖÔÚͬһˮƽ¡£
½áÂÛ£ºÐ£ËÀºóTie2ÊÜÌåµÄ±í´ïÉϵ÷£¬ÓëѪ¹ÜÉú³ÉµÄʱ¼äÏàÎǺϣ¬ÌáʾÆäÔÚÐ£ËÀºóµÄѪ¹ÜÉú³ÉºÍÎȶ¨¹ý³ÌÖÐÆðÁËÒ»¶¨µÄ×÷Óá£
¹Ø¼ü´Ê£ºÐ£ËÀ£»Ñª¹ÜÉú³É£»Ñª¹ÜÉú³ÉËØ1£»Tie2ÊÜÌå

ËïÀö½Ü£¬´ÞÃù£¬Íõ×ôÑÒ£¬·ëк㣬ë½ÚÃ÷£¬³Â·ïÈÙ.Ð£ËÀ´óÊóѪ¹ÜÉú³É¹ý³ÌÖÐѪ¹ÜÉú³ÉËØ1¼°ÆäTie2ÊÜÌåµÄ±í´ï[J].Öйú×éÖ¯¹¤³ÌÑо¿ÓëÁÙ´²¿µ¸´£¬2008£¬12(11):2079-2082 [www.zglckf.com/zglckf/ejournal/upfiles/08-11/11k-2079(ps).pdf]

ÖÐͼ·ÖÀàºÅ:R542.22
ÎÄÏ×±êʶÂë:A
ÎÄÕ±àºÅ:1673-8225
(2008)11-02079-04

ÊÕ¸åÈÕÆÚ£º2007-08-07 ÐÞ»ØÈÕÆÚ£º2007-10-13 (07-50-8-4274/N¡¤A)

Expression of angiopoietin-1 and Tie2 receptor during angiogenesis in rats with myocardial infarction

Abstract

AIM: To investigate the role of angiopoietin-1 (Ang1) and Tie2 receptor in angiogenesis after myocardial infarction through detecting their mRNA expression in normal and infracted myocardium.
METHODS: The experiment was conducted in the laboratory of Biochemistry and Molecular Biology, Medical Department of Peking University from April 2006 to April 2007. Forty male SD rats were randomly divided into acute myocardial infarction model group and sham-operation group. The myocardial infarction model was established in the rats of model group through the ligation of left anterior descending artery, while the rats in sham operation group were braided of the left anterior descending artery without ligation. Five rats in both groups were executed at 3, 7, 14, and 28 days after model establishment. RNA was extracted from the same site of left anterior wall, and the polymerase chain reaction was used to semiquantitatively analyze the Ang1 and Tie2 receptor mRNA expression with GAPDH gene as internal control; meanwhile, the immunohistochemistry was used to detect vascular density in and around infarction area. All the treatments for animals were accorded with the animal ethical standards.
RESULTS: All 40 rats were included in the final analysis. Both Ang1 and Tie2 receptor were expressed in normal myocardium. In the 28 days after myocardial infarction, Ang1 expression kept at almost the same level without changing, but Tie2 receptor expression was slightly elevated at 3 days, reached peak value at 7 days, and returned to the baseline value at 14 days. The vascular density increased both infarction and peri-infarction area at 7 days after acute myocardial infarction, and did not change with time.
CONCLUSION: Tie2 receptor expression is elevated and coincided with angiogenesis after myocardial infarction. It may play a role in the development and stabilization of the blood vessel after myocardial infarction.

Sun LJ, Cui M, Wang ZY, Feng XH, Mao JM, Chen FR.Expression of angiopoietin-1 and Tie2 receptor during angiogenesis in rats with myocardial infarction.Zhongguo Zuzhi Gongcheng Yanjiu yu Linchuang Kangfu 2008;12(11):2079-2082(China)
[www.zglckf.com/zglckf/ejournal/upfiles/08-11/11k-2079(ps).pdf]


0 ÒýÑÔ

Ѫ¹ÜÉú³ÉËØ(angiopoietin ,Ang) ÊǽüÀ´·¢ÏֵĴÙѪ¹ÜÉú³ÉµÄϸ°ûÒò×Ó,Æä¼Ò×å³ÉÔ±°üÀ¨Ang1£¬Ang2£¬Ang3£¬Ang4£¬ÆäÖÐÑо¿×î¶àµÄÊÇAng1¼°ÆäÊÜÌåTie2¡£ÓëѪ¹ÜÄÚÆ¤Éú³¤Òò×Ó²»Í¬,Ang1/Tie2ϵͳ×÷ÓÃÓÚѪ¹ÜÉú³ÉµÄÍíÆÚ½×¶Î£¬ÓÕµ¼ºÍά³ÖÄÚÆ¤Ï¸°ûÇ¨ÒÆ¡¢´æ»î£¬ÔÚѪ¹ÜÐÂÉú¼°ÆäÎȶ¨µÄ¹ý³ÌÖÐÆðÁËÖØÒªµÄ×÷Óᣱ¾ÎÄͨ¹ý½áÔú´óÊó¹Ú×´¶¯Âöǰ½µÖ§ÖÆÔìÐ£ËÀÄ£ÐÍÀ´Ñо¿Ð£ËÀºó¹£ËÀ²¿Î»¼°ÆäÖÜΧ×éÖ¯Ang1/Tie2µÄ±í´ï¼°ÆäÓëѪ¹ÜÉú³ÉµÄ¹ØÏµ£¬´Ó¶øÎªÁÙ´²ÖÎÁÆÌṩ˼·¡£

1 ²ÄÁϺͷ½·¨

Éè¼Æ£ºÍêÈ«Ëæ»ú·Ö×éÉè¼Æ¡£
µ¥Î»£º±±¾©´óѧµÚÈýÒ½ÔºÐÄÄÚ¿Æ¡£
²ÄÁÏ£ºÊµÑéÓÚ2006-04/2007-04ÔÚ±±¾©´óѧҽѧ²¿ÉúÎﻯѧÓë·Ö×ÓÉúÎïѧ»ùÒò×éʵÑéÊÒÍê³É¡£Ñ¡ÓÃÇå½à¼¶ÐÛÐÔSD´óÊó£¬ÌåÖÊÁ¿200~250 g£¨Ðí¿ÉÖ¤SYXK 2002-2002£©£¬¹º×Ô±±¾©´óѧҽѧ²¿ÊµÑ鶯Îﲿ£¬ËÇÑø»·¾³ÎªÎ¶È22~ 25 ¡æ£¬Êª¶È50%~60%£¬×ÔÈ»¹âÕÕ¡£½«40Ö»´óÊóËæ»ú·ÖΪ¼±ÐÔÐ£ËÀ×éºÍ¼ÙÊÖÊõ×é2×飬¸÷×é¾ù·ÖΪ3£¬7£¬14£¬28 d 4¸öʱ¼äµã£¬Ã¿Ê±¼äµã5Ö»´óÊó¡£ÊµÑé¹ý³ÌÖж¯Îï´¦Ö÷ûºÏ¶¯ÎïÂ×Àíѧ±ê×¼¡£
TRIzolÊÔ¼Á¹º×ÔGibco¹«Ë¾¡¢·´×ªÂ¼Ã¸¡¢¶à¾Ûø¹º×Ôinvitrogen¹«Ë¾¡£PCRÒýÎïÓÉÉϺ£Éú¹¤¹«Ë¾ºÏ³É¡£Íÿ¹ÈË¢øÒò×Ó¼°Ð¡Êó¿¹´óÊóalpha-SMA¿¹Ì幺×ÔÖÐɽÉúÎïÊÔ¼Á¹«Ë¾¡£
Éè¼Æ¡¢ÊµÊ©¡¢ÆÀ¹ÀÕߣºÎªÈ«²¿×÷Õߣ¬¾ù¾­¹ýרҵÅàѵ£¬Î´²ÉÓÃä·¨ÆÀ¹À¡£
·½·¨£º
¶¯ÎïÄ£Ðͽ¨Á¢£º°´ÕÕZhang µÈ[1]µÄʵÑé·½·¨ÖƱ¸¶¯ÎïÄ£ÐÍ¡£½«Ð£ËÀ×éSD´óÊóÒÒÃÑÂé×íºó£¬¾­ÐعÇ×óÔµµÚËÄÀß¼äºáÇпÚÈ¡³öÐÄÔ࣬Óڷζ¯ÂöÓë×óÐĶúÖ®¼ä¹Ú×´¶¯Âö×ßÐд¦¾à·Î¶¯Âö¸ù²¿3 mm´¦½áÔúǰ½µÖ§£¬ÒÔ×óÊÒǰ±Ú±ä°×Ϊ±êÖ¾ÖÆ³É¼±ÐÔǰ±ÚÐ£ËÀÄ£ÐÍ£¬»ØÄÉÐÄÔ࣬ÒÀ´Î·ìºÏ¡£ÓÚÊÖÊõ3 dºó¾­³¬Éù¼ì²é֤ʵÊÒ±Ú½Ú¶ÎÐÔÔ˶¯Òì³£ÔÙ´Îɸ²é£¬ÅųýÐ¡Ãæ»ýÐ£ËÀ¼°Î´¹£ËÀÕß¡£Í¬Ê±ÒÔǰ½µÖ§´©Ïßµ«²»½øÐнáÔúÖÆ±¸¼ÙÊÖÊõ×é×÷Ϊ¶ÔÕÕ×é¡£
ÐÄÔ๦Äܼì²â£º¸÷×éʵÑé´óÊóÓÚÐ£ËÀºóµÄ3£¬7£¬14£¬28 d½øÐг¬ÉùÐĶ¯Í¼¼ì²é£¨±±¾©´óѧµÚÈýÒ½ÔºÐÄÄڿƳ¬ÉùÐĶ¯Í¼ÊÒ£©¡£Ê¹ÓÃSeaquoia C256³¬ÉùÒÇ£¨Acuson Co.£©ÏßÕó̽ͷƵÂÊ8MHz£¬Ì½²âÉî¶È2 cm¡£¸¹Ç»ÄÚ×¢É临ºÏÂé×í¼Á£¨3 mL/kg£©È«ÉíÂé×í£¬ÐØ²¿±¸Æ¤£¬ÑöÎԹ̶¨¡£³¬Éù̽ͷÖÃÐØÇ°£¬¶þάÏÔʾÐÄÔà¶ÌÖáÈéÍ·¼¡Ë®Æ½£¬ÔÚ¶þά³¬ÉùÖ¸µ¼ÏÂÓÃMÐͳ¬Éù²â¶¨ÐÄÔà½á¹¹£¬°üÀ¨ÊæÕÅÄ©ÆÚ×óÊÒÄÚ¾¶£¨LVDD£©µÈ£¬Ó¦ÓÃTeichholtz¹«Ê½·¨¼ÆËã×óÊÒÉäѪ·ÖÊý£¨EF£©¡£Ã¿×éԭʼÊý¾ÝÈ¡Á¬Ðø3¸öÐ͝ÖÜÆÚµÄÆ½¾ùÖµ£¬ÓÉר¿ÆÒ½Éú·ÖÎö¡£
×é֯ѧ¼ì²â£ºÓÚ¸÷ʱ¼äµã£¬¸´ºÏÂé×í¼ÁÂé×í´¦ËÀ¶¯ÎѸËÙÈ¡ÆäÐÄÔ࣬×Ô½áÔúÏßϺá¶Ï£¬È¡2 mmºñ¶È¶ÏÃæ½øÐÐ40 g/L¶à¾Û¼×È©¹Ì¶¨£¬ÖƱ¸Ê¯À¯ÇÐÆ¬£¬Í¬Ê±È¡²¿·Ö½øÐÐOCT°üÂñ£¬Í¶ÈëÒºµª30 s£¬ÖƳɱù¶³ÇÐÆ¬-20 ¡æ ³¤ÆÚ±£´æ¡£ÃâÒß×黯¼ì²â¹£ËÀÇøÓòÒÔ¼°¹£ËÀÖܱßÇøÓòѪ¹ÜÊýÁ¿¡ª¡ª¢øÒò×Ó´ú±íѪ¹Ü×ÜÊý£¬¦Á-SMA´ú±í¼¡ÐÔС¶¯ÂöÊýÁ¿¡£Ã¿×éÈ¡5Ö»¶¯Îÿֻ¶¯ÎïÖÆ±¸5ÕÅÇÐÆ¬£¬Ã¿ÕÅÇÐÆ¬Ëæ»ú¹Û²ì3¸öÊÓÒ°£¬¸ß±¶¾µÏ¼ÆÊýѪ¹ÜÃܶȣ¬È¡Æäƽ¾ùÖµ¡£
Ðļ¡×éÖ¯×ÜRNAµÄÌáÈ¡£ºÊ£ÓàÐÄÔಿ·ÖÈ¡Æä¹£ËÀÐļ¡×éÖ¯£¬ÀûÓÃTrizolÌáÈ¡×ÜRNA£¨Ïê¼ûTRIzolÊÔ¼Á˵Ã÷Ê飩£¬¾­µçÓ¾¼ø¶¨ÆäÍêÕûÐÔ£¬ÀûÓÃ×ÏÍâ¹â·Ö¹â¹â¶È¼Æ²â¶¨A260ÓëA280µÄ±ÈÖµ£¬²¢¼ÆËãÆäŨ¶È¡£
Ang1/Tie2 mRNAˮƽ¼ì²â£º¸÷È¡2 ¦Ìg×ÜRNA¾­·´×ªÂ¼·´Ó¦Éú³ÉcDNA£¬ÒÔ2 ¦ÌL cDNAΪģ°å½øÐÐRT-PCR£¬×ÜÌå»ýΪ50 ¦ÌL£¬¼ì²âAng1£¬Tie2±í´ïË®Æ½ËæÊ±¼äµÄ±ä»¯Çé¿ö¡£Ang1ÒýÎïÐòÁУº5¡¯-GGA GCA TGT GAT GGA AAA TTA-3¡¯/5¡¯-TGT GTT TTC CCT CCA TTT CTA-3¡¯£»Tie2ÒýÎïÐòÁУº5¡¯-ATG GAC TCT TTA GCC GGC TTA-3¡¯/5-CCT TAT AGC CTG TCC TCG AA-3¡¯£»ÒÔ¸ÊÓÍÈ©-3-Á×ËáÍÑÇâø£¨GAPDH£©×÷ΪÄÚ²ÎÕÕ£¬ÆäÒýÎïÐòÁÐΪ£º5¡¯-GGA AAG CTG TGG CGT GAT GG-3¡¯/5¡¯-GTA GGC CAT GAG GTC CAC CA-3¡¯¡£À©ÔöƬ¶ÎµÄ³¤¶È·Ö±ðΪ360 bp£¬337 bp£¬413 bp¡£PCR²úÎïÓÃ15 g/LÇíÖ¬ÌÇÄý½ºµçÓ¾½øÐзÖÎö¡£Ã¿¸öʱ¼äµã¸÷È¡5Ö»´óÊó£¬Ã¿Ö»È¡3´ÎµçÓ¾½á¹û½øÐмÆË㼰ͼÏñ´¦Àí£¬ÒÔGAPDHΪ²ÎÕÕ½øÐа붨Á¿¡£
Ö÷Òª¹Û²ìÖ¸±ê£º´óÊó¼±ÐÔÐ£ËÀºóÐŦÄÜ£¬¹£ËÀÇøÓò¼°Æä¹£ËÀÖÜΧѪ¹ÜÉú³ÉËæÊ±¼äµÄ±ä»¯ÒÔ¼°¹£ËÀÐļ¡×éÖ¯ÖÐAng1/Tie2 mRNAµÄ±í´ï¡£
ͳ¼ÆÑ§·½·¨£ºÓɵÚÒ»×÷Õß²ÉÓÃSPSS 10.0 ͳ¼ÆÈí¼þ½øÐжÀÁ¢Ñù±¾t¼ìÑ飬½á¹ûÒÔ_x¡Às±íʾ£¬P < 0.05ÈÏΪ²îÒì¾ßÓÐÏÔÖøÐÔÒâÒå¡£

2 ½á¹û

2.1 ʵÑ鶯ÎïÊýÁ¿·ÖÎö ÈëÑ¡´óÊó¹²46Ö»£¬ÊµÑéÖÐÒò¶¯ÎïËÀÍöµÈ¸÷ÖÖÔ­ÒòÍÑʧ¹²6Ö»£¬¹²ÓÐ40Ö»´óÊó½øÈëʵÑé½á¹û·ÖÎö£¬Ã¿×éÖи÷¼ì²âʱ¼äµã¾ùΪ5Ö»¡£
2.2 Á½×é´óÊóÐij¬ÉùÓ°Ïñѧ±íÏÖËÀÍö Ð£ËÀºó3 d¼´¿É¿´µ½¹£ËÀÊÒ±Ú½Ú¶ÎÐÔÔ˶¯Òì³££¬²¢ËæÊ±¼äÍÆÒÆ³öÏÖÐÄÊÒÄÚ¾¶½øÐÐÐÔÀ©ÕÅ£¬ÐŦÄܽøÐÐÐÔ¶ñ»¯¡£¾ßÌåÖ¸±ê¼û±í1¡£

 

2.3 Ð£ËÀºó¹£ËÀ²¿Î»¼°Æä¹£ËÀÖÜÎ§ÇøÓòµÄѪ¹ÜÉú³ÉÇé¿ö ¼±ÐÔÐ£ËÀºó7 d£¬ ¢øÒò×ÓȾɫÑôÐÔµÄѪ¹ÜÊýÁ¿ÓÚ¹£ËÀÇø¼°¹£ËÀÖܱßÇøÓò¾ùÃ÷ÏÔÔö¶à£¬ÕâÖÖÊýÁ¿Ôö¶à²¢²»ËæÊ±¼äµÄÑÓ³¤¶ø¸Ä±ä£¬Î¬³ÖÔÚͬһˮƽ£»¦Á-SMAȾɫÑôÐÔѪ¹Ü¼ÆÊýÓÐÏàËÆ±íÏÖ¡£¼û±í2¡£ÿ

 

2.4 Ð£ËÀºó¹£ËÀÐļ¡×éÖ¯ÖÐAng1/Tie2 mRNAµÄ±í´ï ¼ûͼ1¡£

 

µçÓ¾½á¹û±íÃ÷£ºÌáÈ¡µÄ×ÜRNA³ÊÏÖÇåÎúµÄ28SºÍ18SÌõ´ø£¬Á½Õß±ÈÀýԼΪ1.5¡Ã1¡£A260/A280¾ù´óÓÚ1.7¡£¸ù¾ÝA260Öµ¼ÆËãRNAµÄº¬Á¿¡£RT-PCRµÄ½á¹ûÏÔʾ£¬Tie2£¬Ang1ÔÚ¼ÙÊÖÊõ×éÐļ¡×éÖ¯ÖоùÓв»Í¬Ë®Æ½µÄ±í´ï£¬¼±ÐÔÐ£ËÀ×éÖжþÕߵıí´ïËæÊ±¼ä±ä»¯¶ø²»Í¬: Ang1µÄ±í´ïÔÚ¸÷ʱ¼äµã²¢ÎÞÏÔÖø±ä»¯£»Tie2ÊÜÌå±í´ï3 dÂÔÓÐÉý¸ß£¬ÓÚ7 dºó´ï·å£¬14 dºó»Ö¸´Õý³££¬¼ûͼ2¡£

 

3 ÌÖÂÛ

Ѫ¹ÜÐÂÉúÊǽüÄêÀ´ÖÎÁÆÈ±ÑªÐÔ¼²²¡µÄÖØÒªÑо¿·½Ïò¡£Ang1ÊǽüÄêÀ´·¢ÏÖµÄѪ¹ÜÄÚÆ¤Ñ¡ÔñÐÔÀÒ°±Ëἤø Tie2ÊÜÌåµÄÅäÌå[2]£¬ÔÚÅß̥Ѫ¹Ü·¢Éú¹ý³ÌÖУ¬Ang1ÓëѪ¹ÜÄÚÆ¤Éú³¤Òò×ÓÒ»ÑùÓµÓÐÖØÒªµÄµØÎ»£¬²»Í¬µÄÊÇAng1×÷ÓÃÓÚѪ¹ÜÉú³ÉµÄÍíÆÚ½×¶Î£¬´Ù½øÁ˳õ¼¶Ñª¹ÜµÄ³ÉÊìºÍÎȶ¨£¬´Ó¶øÐγɳÉÊìµÄѪ¹Ü½á¹¹¡£¼±ÐÔÐ£ËÀ×÷ΪһÖÖÑÏÖØÈ±ÑªÐÔ¼²²¡£¬ÖÎÁÆÐÔѪ¹ÜÐÂÉú¸ÄÉÆ¹£ËÀÐÄÔ๦ÄÜÒѾ­³ÉΪһÖÖÖØÒªÊֶΡ£È»¶øÃ¤Ä¿µÄѪ¹ÜÉú³ÉÖÎÁÆÒ²»áÔì³ÉÑÏÖØ²»Á¼ºó¹û[3]¡£Ñо¿Ö¤Ã÷Ang1ͬÑù²ÎÓëÁ˳ÉÌå×é֯Ѫ¹ÜÉú³ÉµÄ²¡ÉúÀí¹ý³Ì£¬Äܹ»¶Ô¿¹Ñª¹ÜÄÚÆ¤Éú³¤Òò×ÓÐγÉÉøÂ©Ñª¹ÜµÄ±×²¡[4]£¬´Ó¶øÊ¹µÃÖÎÁÆÐÔµÄѪ¹ÜÐÂÉú³ÉΪ¿ÉÄÜ¡£
±¾ÊµÑ齨Á¢´óÊó¼±ÐÔÐ£ËÀÄ£ÐÍ£¬²ÉÓÃRT-PCR·½·¨¼ì²â¼±ÐÔÐ£ËÀºóÐļ¡×éÖ¯Ang1/Tie2±í´ïË®Æ½ËæÊ±¼äµÄ±ä»¯£¬½á¹û·¢ÏÖÕý³£Ðļ¡×éÖ¯ÖпɼûAng1/Tie2µÄ±í´ï£¬ÔÚÐļ¡È±ÑªÈ±ÑõµÄ²¡ÀíÌõ¼þÏ£¬Ang1µÄ±í´ïˮƽÎÞÃ÷ÏԱ仯£¬¶øTie2±í´ï³ÊÏÖÒ»¶¨µÄʱÏàÐԱ仯£¬ÔçÆÚ±í´ïÓÐËùÉý¸ß£¬ËæÊ±¼äÑÓ³¤¶øÖð½¥»Ö¸´µ½Õý³£Ë®Æ½¡£
ÌåÍâÊÔÑé±íÃ÷£¬È±ÑõºÍѪ¹ÜÄÚÆ¤Éú³¤Òò×ÓÄܹ»µ÷½Ú²»Í¬Ï¸°ûµÄAng1/Tie2 ˮƽµÄ±í´ï¡£ÀýÈ磬ȱÑõºÍѪ¹ÜÄÚÆ¤Éú³¤Òò×ÓÄܹ»´Ù½øÊÓÍøÄ¤ pericytes ϸ°ûAng1 mRNAˮƽÔÚ¶Ìʱ¼äÄÚѸËÙ±í´ï£¬È»ºóѸËÙϽµ£¬¶øTie2 mRNAµÄ±í´ïÄܹ»³ÖÐø½Ï³¤Ê±¼ä£»ÔÚÅ£µÄÖ÷¶¯ÂöÄÚÆ¤Ï¸°ûÖÐÔò·¢ÏÖ£¬Ang1ºÍTie2ˮƽÔÚȱÑõºÍѪ¹ÜÄÚÆ¤Éú³¤Òò×Ӵ̼¤µÄÇé¿öϾùÎÞÃ÷ÏԱ仯[5]¡£WillamµÈ[6]µÄÌåÍâʵÑéÔòÖ¤Ã÷Ñ×Ö¢ºÍȱÑõÄܹ»ÓÕµ¼È˹Ú״΢Ѫ¹ÜÄÚÆ¤Ï¸°ûTie2ÊÜÌåµÄ±í´ïÉϵ÷£¬²¢³ÊÏÖʱ¼äÒÀÀµÐÔ¡£
ÔÚÌåÄÚÊÔÑéÖУ¬ShyuµÈ[7]·¢ÏÖ£¬ÔÚ¼±ÐÔÐ£ËÀ´óÊóµÄ·Ç¹£ËÀÐļ¡×éÖ¯ÖÐTie2 µÄ±í´ïˮƽûÓб仯£¬¹£ËÀÐļ¡ÖÜΧTie2µÄˮƽÃ÷ÏÔÉϵ÷£¬¶øAng1µÄˮƽÎÞÂÛÔÚ¹£ËÀ×éÖ¯»òÕß¹£ËÀÖÜΧ×éÖ¯ÖоùÎÞÃ÷ÏԱ仯¡£±¾ÊµÑé½á¹ûÓëÖ®ÏàËÆ¡£Í¬Ñù£¬ÔÚȱѪÔÙ¹à×¢ºóµÄÐļ¡×éÖ¯ÖУ¬Ò²·¢ÏÖÁËTie2 ÊÜÌåµÄÉϵ÷¶øAng1µÄ±í´ïˮƽ²»±ä[8]¡£ÁíÓв¿·ÖÑо¿ÏÔʾ²»Í¬½á¹û£¬´óÊó¹£ËÀÇø¼°¹£ËÀÖÜÎ§ÇøÐļ¡×éÖ¯ÖеÄTie2 ˮƽÔÚ¹£ËÀºó³ÖÐøÐÔÔö¸ß£¬¶øAng1ˮƽϽµ[9]£¬·ÖÎö¸Ã½á¹û¿ÉÄÜÓëÊÔÑéËù²ÉÓõÄʱ¼äµã²»Í¬ËùÖ£¬±¾ÎIJÉÓÃÁËÐ£ËÀºó3 d×÷Ϊ×î³õµÄ¹Û²ìµã£¬¶ø¸ÃÑо¿¹Û²ìµÄÔòÊÇÐ£ËÀºóµÄ24 hµÄ±ä»¯¡£
±¾ÊµÑéͬʱ·¢ÏÖ£¬Ð£ËÀºó´æÔÚ×Ô·¢ÐÔµÄѪ¹ÜÉú³É£¬ÆäÉú³Éʱ¼äÓëTie2±í´ïµÄÉý¸ß³ÊÏÖÒ»¶¨µÄÏà¹ØÐÔ£¬µ«²¢²»ËæTie2±í´ïˮƽµÄÖð½¥Õý³£»¯¶øÏûÍË¡£Ñª¹ÜÄÚÆ¤Éú³¤Òò×ÓÓë Ang1/Tie2²ÎÓëÁËȱѪ×éÖ¯µÄѪ¹ÜÉú³É¹ý³Ì¡£ÒÑÓÐÎÄÏ×±¨µÀ¼±ÐÔÐ£ËÀ×éÖ¯¼°ÑªÑ­»·¼°Æä¹£ËÀÐļ¡×éÖ¯¼äÒºÖеÄѪ¹ÜÄÚÆ¤Éú³¤Òò×ÓˮƽÉý¸ß[10-11]£¬Ð£ËÀºóÄÚÔ´ÐÔµÄѪ¹ÜÄÚÆ¤Éú³¤Òò×Ӹ߱í´ï´Ù½øÄÚÆ¤Ï¸°û·ÖÁÑ£¬ÐγÉÉøÂ©ÐÔѪ¹Ü¡£±¾Ñо¿·¢ÏÖ¹£ËÀÐļ¡×éÖ¯ÖÐTie2ˮƽÉý¸ß£¬ÕâÒ»½á¹ûÔÙÒ»´ÎÌáʾ²»Í¬µÄѪ¹ÜÉú³ÉÒò×ÓÓëÆäÊÜÌ干ͬ²ÎÓë¹£ËÀºóÐļ¡×éÖ¯µÄѪ¹ÜÐÂÉú¡£Ð£ËÀºóTie2ˮƽµÄÔö¸ß¿ÉÄÜÊÇȱѪȱÑõµ¼ÖÂÄÚÔ´ÐÔµÄѪ¹ÜÉú³É±£»¤»úÖÆµÄ¼¤»î¡£ÓÉÓÚAng1/Tie2ÔÚѪ¹ÜÉú³ÉºÍά³Ö¹ý³ÌÖÐÊÇÒ»¸öÍêÕûµÄÌåϵ£¬×÷ÕßÍÆ²âÉϵ÷µÄTie2ÊÜÌåÓëÄÚÔ´ÐÔAng1µÄ½áºÏ´Ù½øÑª¹Ü³ÉÊì¡¢Îȶ¨¿ÉÄÜÊÇѪ¹ÜÉú³ÉºÍС¶¯ÂöÉú³ÉµÄÖØÒªÔ­Òò£¬µ«ÈÔÐè½øÒ»²½µÄTie2ÊÜÌå×è¶ÏʵÑéÀ´Ö¤Ã÷¡£Tie2Ö÷Òª±í´ïÔÚÄÚÆ¤Ï¸°ûÉÏ£¬ÔÚ³ÉÌåµÄѪ¹Ü×éÖ¯ÖУ¬Tie2ÆðÁËÖØÒªµÄ×÷Óã¬ËüÄܹ»ÔÚȱѪ¡¢È±ÑõÒÔ¼°Ñ×Ö¢´æÔÚµÄÇé¿öÏÂÉϵ÷[5]¡£Í¬Ê±Tie2Ò²±í´ïÔÚÄÚÆ¤Ï¸°ûµÄǰÌåϸ°ûÉÏ[12]£¬ÕâЩϸ°ûÔÚѪ¹ÜµÄ·¢Óý¹ý³ÌÖбز»¿ÉÉÙ[13]£¬Òò´Ë²»ÄÜÅųýÄÚÆ¤×æÏ¸°û¶¯Ô±ÔÚÐĹ£ºóѪ¹ÜÉú³É¹ý³ÌÖеÄ×÷Óá£ÁíÍ⣬ÓÐÑо¿±íÃ÷Ѫ¹ÜÄÚÆ¤Éú³¤Òò×Ó¿ÉÒÔ´Ù½øÑª¹Üƽ»¬¼¡Ï¸°ûTie2ÊÜÌåˮƽµÄÉϵ÷£¬´Ó¶ø´Ù½øAng1½éµ¼µÄTie2ÊÜÌåµÄÁ×Ëữ´Ó¶ø·¢»ÓÆäÉúÎïѧЧӦ£¬Í¬Ê±Ò²Äܹ»´Ù½ø¼¡Ï¸°ûTie2ÊÜÌåµÄ±í´ï£¬´Ó¶øÔÚAng1µÄ×÷ÓÃϲúÉúÇ¨ÒÆ[14]¡£¶øTie2ÊÜÌ弤»îºó£¬Ang1´ÓÄÚÆ¤Ï¸°û±íÃæÊÍ·Å£¬²¢ÇÒ¾Û¼¯ÔÚÖÜΧµÄ»ùÖʵ±ÖÐ[15]¡£Òò´Ë£¬ÔÚѪ¹ÜÄÚÆ¤Éú³¤Òò×ÓºÍAng1µÄ¹²Í¬×÷ÓÃÏ£¬Äܹ»Ö±½Ó¶Ô¼¡Ï¸°û»òÕßËûÃǵÄǰÌåϸ°ûÆð×÷Ó㬴ӶøÐγÉеÄÎȶ¨µÄѪ¹Ü¡£
½üÄêÀ´²»Í¬µÄÑо¿ÁìÓò£¬Èç´óÄÔ[8£¬16]£¬Ö«Ìå[17]£¬ÐÄÔàµÈ×éÖ¯ÖÐ[15£¬18]£¬ÒѾ­Â½ÐøÓб¨µÀÔÚȱѪȱÑõÌõ¼þÏ£¬Ôö¼ÓѪ¹ÜÄÚÆ¤Éú³¤Òò×Ó»òAng1/Tie2ˮƽÄܹ»´Ù½øÑª¹ÜÉú³É£¬¸ÄÉÆ×éÖ¯ÖØ¹¹£¬¸ÄÉÆÆ÷¹Ù¹¦ÄÜ¡£±¾Ñо¿Í¨¹ý¶Ô¼±ÐÔÐ£ËÀºó¹£ËÀÐļ¡×éÖ¯ÖÐAng1/Tie2±í´ïˮƽ½øÐÐÑо¿±íÃ÷£¬Tie2ÊÜÌåµÄ±í´ïÔÚijÖ̶ֳÈÉÏÉϵ÷£¬¶øAng1±í´ïµÄ²»³ä·Ö¡£ÒÑÖªTie2ÊÜÌåµÄ×÷ÓÃÓëÆäÅäÌåAng1Ãܲ»¿É·Ö£¬ºóÕß±í´ï²»³ä·Ö¿ÉÄÜΪÓÐЧѪ¹ÜÉú³É²»×ãµÄÔ­ÒòÖ®Ò»¡£±¾ÊµÑéΪÁÙ´²¼±ÐÔÐ£ËÀAng1»ùÒòÖÎÁÆÐÔѪ¹ÜÉú³ÉÌṩÁËÒ»¶¨µÄÀíÂÛ»ù´¡£¬Í¬Ê±Ò²ÌáʾÁËÔÚѪ¹ÜÉú³É¹ý³ÌÖС¢Öî¶àѪ¹ÜÉú³ÉÒò×Ó²ÎÓëµÄ¸´ÔÓ»·¾³Ï£¬ÈçºÎºÏÀíÓ¦Óø÷ÖÖÒò×ÓʹÆä·¢»Ó×î¼ÑµÄѪ¹ÜÉú³É×÷Óý«³ÉΪ½ñºóÑо¿µÄÖØ´ó¿ÎÌâ¡£

4 ²Î¿¼ÎÄÏ×

1 Zhang S, Zhang P, Guo J,et al. Enhanced cytoprotection and angiogenesis by bone marrow cell transplantation may contribute to improved ischemic myocardial function. Eur J Cardiothorac Surg 2004; 25(2):188-195
2 Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87(7):1161-1169
3 Matsuno H, kozana O, Yoshimi N, et al. Lack of alpha2-antiplasmin promotes pulmonary heart failure via overrelease of VEGF after acute myocardial infarction. Blood 2002;100(7):2487-2493
4 Thurston G, Suri C, Smith K, et al. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1.Science 1999;286(5449):2511-2514
5 Park YS, Kim NH, Jo I. Hypoxia and vascular endothelial growth factor acutely up-regulate angiopoietin-1 and Tie2 mRNA in bovine retinal pericytes.Microvasc Res 2003;65(2):125-131
6 Willam C, Koehne P, J¨¹rgensen JS, et al. Tie2 receptor expression is stimulated by hypoxia and proinflammatory cytokines in human endothelial cells.Circ Res 2000;87(5):370-377
7 Shyu KG, Liang YJ, Chang H, et al. Enhanced expression of angiopoietin-2 and the Tie2 receptor but not angiopoietin-1 or the Tie1 receptor in a rat model of myocardial infarction.J Biomed Sci 2004;11(2):163-171
8 Shyu KG, Chang CC, Wang BW, et al. Increased expression of angiopoietin-2 and Tie2 receptor in a rat model of myocardial ischaemia/reperfusion. Clin Sci (Lond) 2003;105(3):287-294
9 Sandhu R, Teichert-Kuliszewska K, Nag S, et al. Reciprocal regulation of angiopoietin-1 and angiopoietin-2 following myocardial infarction in the rat.Cardiovasc Res 2004;64(1):115-124
10 Xu X, Li J, Simons M, et al. Expression of vascular endothelial growth factor and its receptors is incresase, but microvascular relaxation is impaired in patients after acute myocardial ischemia. J Thoracic Cardiovasc Sug 2001;121(4):735-742
11 Matsunaga T, Warltier DC, Tessmer J, et al. Expression of VEGF and angiopoietins-1 and -2 during ischemia-induced coronary angiogenesis. Am J Physiol Heart Circ Physiol 2003;285(1):H352-H358
12 Dumont DJ, Yamaguchi TP, Conlon RA, et al. tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors.Onconege 1992; 7(8):1471-1480
13 Puri MC, Rossant J, Alitato K, et al. The receptor tyrosine kinase TIE is required for integrity and survival of vascular endothelial cells. EMBO J. 1995;14(23):5884-5891
14 Metheny-Barlow LJ, Tian S, Hayes AJ, et al. Direct chemotactic action of angiopoietin-1 on mesenchymal cells in the presence of VEGF. Microvasc Res 2004; 68(3):221-230
15 Bogdanovic E, Nguyen VP, Dumont DJ. Activation of Tie2 by angiopoietin-1 and angiopoietin-2 results in their release and receptor internalization.J Cell Sci 2006;119(Pt 17):3551-3560
16 Zacharek A, Chen J, Cui X,et al. Angiopoietin1/Tie2 and VEGF/Flk1 induced by MSC treatment amplifies angiogenesis and vascular stabilization after stroke.J Cereb Blood Flow Metab 2007;27(10): 1684-1691
17 Shyu KG, Manor O, Magner M, et al. Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation 1998;98(19):2081-2087
18 Takahashi K, Ito Y, Morikawa M, et al. Adenoviral-Delivered angiopoietin-1 reduces the infarction and attenuates the progression of cardiac dysfunction in the rat model of acute myocardial infarction. Molecular Therapy 2003;8(4):584-592


¡¶Öйú×éÖ¯¹¤³ÌÑо¿ÓëÁÙ´²¿µ¸´¡·ÔÓÖ¾Éç
µØÖ·£ºÉòÑô1200ÓÊÕþÐÅÏä Óʱࣺ110004 ´«Õ棺+86 24 23394178